BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26208485)

  • 21. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
    Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study.
    Le Ray I; Dell'Aniello S; Bonnetain F; Azoulay L; Suissa S
    Breast Cancer Res Treat; 2012 Sep; 135(2):603-9. PubMed ID: 22903687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant hormonal therapy in perimenopausal patients.
    Pinto Marín A; Ballesteros García AI; Izarzugaza Perón Y; Mansó Sánchez L; López-Tarruella Cobo S; Zamora Auñón P
    Adv Ther; 2011 Sep; 28 Suppl 6():39-49. PubMed ID: 21922394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decision-making impairments in breast cancer patients treated with tamoxifen.
    Chen X; Li J; Chen J; Li D; Ye R; Zhang J; Zhu C; Tian Y; Wang K
    Horm Behav; 2014 Jul; 66(2):449-56. PubMed ID: 25036869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost effectiveness of tamoxifen in the prevention of breast cancer.
    Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
    Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function.
    Manni A; Pearson OH
    Cancer Treat Rep; 1980; 64(6-7):779-85. PubMed ID: 6775808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB; Feuer EJ; Harlan LC; Abrams J
    J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity and endocrine therapy: host factors and breast cancer outcome.
    Goodwin PJ
    Breast; 2013 Aug; 22 Suppl 2():S44-7. PubMed ID: 24074791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.
    Kim HS; Yom CK; Kim HJ; Lee JW; Sohn JH; Kim JH; Park YL; Ahn SH
    Breast Cancer Res Treat; 2010 Jun; 121(3):777-88. PubMed ID: 19806450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Tolerance of Tamoxifen as an adjuvant therapy and long-term follow up of 55 premenopausal breast cancer women, cared for at the Institut de cancérologie de Lorraine, treated with Tamoxifen].
    Sebaoun P; Frederic M; Weryha G; Hamdaoui SE; Salleron J; Lesur A
    Bull Cancer; 2019 Dec; 106(12S1):S75-S100. PubMed ID: 32008741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    ; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
    J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
    J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen.
    Paganini-Hill A; Clark LJ
    Breast Cancer Res Treat; 2000 Nov; 64(2):165-76. PubMed ID: 11194452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma.
    Nakhlis F; Lazarus L; Hou N; Acharya S; Khan SA; Staradub VL; Rademaker AW; Morrow M
    J Am Coll Surg; 2005 Nov; 201(5):688-94. PubMed ID: 16256910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
    Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Heck D; Menzel C; Jakesz R; Seifert M; Hubalek M; Pristauz G; Bauernhofer T; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Hochreiner G; Forsthuber EP; Fesl C; Greil R;
    Lancet Oncol; 2011 Jul; 12(7):631-41. PubMed ID: 21641868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
    J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
    Fisher B; Dignam J; Wolmark N; Wickerham DL; Fisher ER; Mamounas E; Smith R; Begovic M; Dimitrov NV; Margolese RG; Kardinal CG; Kavanah MT; Fehrenbacher L; Oishi RH
    Lancet; 1999 Jun; 353(9169):1993-2000. PubMed ID: 10376613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers.
    Reh A; Oktem O; Oktay K
    Fertil Steril; 2008 Nov; 90(5):1635-9. PubMed ID: 18166178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian cysts during tamoxifen use may affect the prognostic markers of premenopausal breast cancer.
    Han W; Kim H; Ku SY; Kim SH; Choi YM; Kim JG; Moon SY
    Gynecol Endocrinol; 2013 Jan; 29(1):16-9. PubMed ID: 22812679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.